UCare’s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare formularies (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for the Medicare formularies are tentative until UCare receives final CMS approval.

Key:

Medicare: UCare Medicare, UCare Medicare with Fairview and North Memorial, UCare Group Medicare, EssentiaCare, Minnesota Senior Health Options (MSHO) & Connect + Medicare

Medical Assistance: PMAP, MnCare, MSC+ & Connect

Exchange: UCare Individual and Family Plans

F: Formulary

NF: Non-formulary

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

|  |
| --- |
| New Drug Review  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug**  | **Indication** | **Formulary Coverage** | **Effective Date** |
| Attruby (acoramidis) | Treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduced cardiovascular death and cardiovascular-related hospitalization. | Medicare: FormularyMedical Assistance: Non-FormularyExchange: Formulary w/PA & QL | NA |
| Alhemo (concizumab) | Routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 years and older with hemophilia A or B, both with or without inhibitors to Factor VIII or IX respectively. | Medicare: FormularyMedical Assistance: Formulary w/PAExchange: Formulary w/PA | NA |
| Hympavzi (marstacimab) | Routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 years and older with hemophilia A or B, without inhibitors to Factor VIII or IX respectively. | Medicare: Non-FormularyMedical Assistance: Non-FormularyExchange: Non-Formulary  | NA |
| Qfitlia (fitusiran) | Routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 years and older with hemophilia A or B, both with or without inhibitors to Factor VIII or IX respectively. | Medicare: Non-FormularyMedical Assistance: Non-FormularyExchange: Non-Formulary  | NA |
| Crenessity (crinecerfont) | adjunct treatment to glucocorticoid (GC) replacement in adults and pediatrics 4 years and older with classic congenital adrenal hyperplasia (CAH) | Medicare: Non-FormularyMedical Assistance: Non-FormularyExchange: Non-Formulary  | NA |
| Revuforj (revumenib) Protected Class | treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in patients aged ≥ 1 year | Medicare: Formulary w/PAMedical Assistance: Formulary w/PAExchange: Formulary w/PA | NA |
| Tryngolza (olezarsen) | An adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) | Medicare: Non-FormularyMedical Assistance: Non-FormularyExchange: Non-Formulary  | NA |
| Vafseo (vadadustat) | Treatment of anemia due to chronic kidney disease (CKD) in adults receiving dialysis for ≥ 3 months | Medicare: Non-FormularyMedical Assistance: Non-FormularyExchange: Non-Formulary  | NA |

**Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 10/1/2025.**

|  |
| --- |
| New Indications Review  |

|  |  |  |
| --- | --- | --- |
| **Drug** | **Current formulary status** | **Recommendation** |
| **Dupixent** (dupilumab) 200 & 300 mg SQ inj for chronic spontaneous urticaria | F: Medicare, PPO, IFPMA - PDL | No change |
| **Nucala** (mepolizumab) 100 mg SQ inj for COPD with an eosinophilic phenotype | NF: Medicare, PPOF: IFPMA - NP | No change |
| **Jivi** (recombinant antihemophilic factor, pegylated-aucl) for hemophilia A in pediatric patients = 7 years age expansion | NF: Medicare, PPOF: IFP, MA | No change |
| **Zynyz** (retifanlimab) 25 mg/mL IV vials for squamous cell carcinoma of the anal canal | NF: All lines of business | No change |
| **Susvimo** (ranibizumab) 100 mg/mL vials for diabetic retinopathy | NF: All lines of business | No change |
| **Welireg** (belzutifan) 40 mg tablets for pheochromocytoma or paraganglioma | F: All lines of business | No change |
| **Nubeqa** (darolutamide) 300 mg tablets approved as a single agent for metastatic castration sensitive prostate cancer | F: all lines of business | No change |
| **Gamifant** (emapalumab) 5 mg/mL & 25 mg/mL IV vials for hemophagocytic lymphohistiocytosis/macrophage activation syndrome in known or suspected Still’s disease | NF: all lines of business | No change |
| **Mavyret** (glecaprevir/pibrentasvi) 100-40 mg tablets and 50-20 mg oral pellets for acute hepatitis C | F: Medicare, PPO, IFPMA - PDL | No change |
| **Mresvia** (Respiratory Syncytial Virus Vaccine) 50 mcg/0.5 mL injection for prevention of RSV in individuals 18-59 years of age at increased risk of disease | F: all lines of business | No change |
| **Tybost** (cobicistat) 90 & 150 mg tablets for HIV in patients = 14kg indication expansion | NF: all lines of business | No change |
| **Datroway** (datopotamab deruxtecan) 100 mg IV vial for EGFR-mutated non-small cell lung cancer | NF: All lines of business | No change |
| **Keytruda** (pembrolizumab) 25 mg/mL IV vial for resectable locally advanced head & necksquamous cell cancer whose tumors express PD-L1I | NF: All lines of business | No change |
| **Monjuvi** (tafasitamab) 200 mg IV vial in combo with lenalidomide & rituximab for relapsed or refractory follicular lymphoma | NF: All lines of business | No change |
| **Dupixent** (dupilumab) 300 mg SQ injection for bullous pemphigoid | F: Medicare, PPO, IFPMA - PDL | No change |

|  |
| --- |
| New Generics Review  |

|  |  |  |
| --- | --- | --- |
| **Drug** | **Rationale/Alternative** | **Recommendation** |
| Aptiom (**eslicarbazepine**) 200, 400, 600, & 800 mg tablets for partial-onset seizures | Generic competition for Aptiom has launched, with at least 6 manufacturers marketing eslicarbazepine | F: Medicare, PPONF: IFP, MA |
| Qsymia (**phentermine-topiramate**) 3.75-23, 7.5-46, 11.25-69, & 15-92 mg ER capsules for chronic weight management | Two manufacturers have launched generic alternatives of phentermine/topiramate capsules. The generics are still considerably higher net cost than the brand was before generic entry.  | NF: all lines of business |
| Promacta (**eltrombopag**) 12.5 & 25 mg packets for suspension & 12.5, 25, 50, & 75 mg tablets for chronic immune thrombocytopenia (ITP), thrombocytopenia in hepatitis C, & severe aplastic anemia | A single generic manufacturer has launched eltrombopag for all strengths of the tablets and packets for suspension. The first manufacturer has 180-day exclusivity, and significant reductions in price are not anticipated until after that expires. The new generic is approximately 10% reduction in AWP list price and 21% for WAC price. | F: all lines of business |
| Jynarque (**tolvaptan**) 15 & 30 mg tablets & multi-strength therapy packs for autosomal dominant polycystic kidney disease | Generic tolvaptan, the equivalent of Jynarque, recently launched and is indicated for autosomal dominant polycystic kidney disease.  | F: IFP, MANF: Medicare, PPO |
| Complera (**emtricitabine-rilpivirine-tenofovir df**) 200-25-300 mg tablets for HIV-1 infection | A new generic for combination HIV treatment, emtricitabine/rilpivirine/tenofovir DF, has launched at approximately a 10% WAC discount to the branded agent.  | F: all lines of business |
| Tasigna (n**ilotinib**) 50, 150, & 200 mg capsules for Philadelphia chromosome positive chronic myeloid leukemia | A new generic nilotinib has launched for all tablet strengths at a 5% (AWP) to 9% (WAC) discount to the branded agent.  | F: all lines of business |
| **Merilog** (insulin aspart-szjj) 100unit/mL pens & vials(Novolog biosimilar) | A biosimilar insulin aspart product has launched in Merilog. | NF: all lines of business |
| Fycompa (**perampanel**) 2, 4, 6, 8, 10, & 12 mg tablets for epilepsy | A generic perampanel (Fycompa equiv) product has launched at a 13% discount to the brand product. | NF: IFP, MAF: Medicare, PPO |
| Xarelto (**rivaroxaban**) 1 mg/mLoral suspension foranticoagulation | Rivaroxaban 1 mg/mL oral suspension recently launched. Similar to the generic 2.5 mg oral tablets, brand Xarelto coverage will be maintained to continue to qualify for rebates on more common and still brand-only strengths | F: IFPNF: Medicare, PPO, MA |
| Eprontia (**topiramate**) 25 mg/mL oral solution for epilepsy & migraine | A generic topiramate 25 mg/mL oral solution has launched.  | NF: all lines of business |
| **Imuldosa** (ustekinumab-srlf) 45 mg/0.5mL PFS, 90 mg/mL PFS & 130 mg/26 mL IV vial and Pyzchiva (ustekinumab-ttwe) 45 mg/0.5 mL SQ vial for variousinflammatory conditions | Another ustekinumab biosimilar launched, Imuldosa, by Accord biopharma. Imuldosa is available as a subcutaneous solution in a prefilled syringe and as a vial for intravenous use. A new biosimilar dosage form of Pyzchiva also launched, now as a vial for subcutaneous use.  | NF: all lines of business |
| **Zepbound** (tirzepatide) 12 mg/0.5 mL & 15 mg/0.5 mL SQ vials for weight management | Two new tirzepatide strengths recently launched, with both subcutaneous solutions only having AWP pricing and only available through the manufacturer for self-pay patients and are not contracted for clients who include weight loss coverage. | NF: Medicare, PPO, IFPMA: NP |
| **Carbzah** (carbinoxamine) 4 mg/5 mL oral solution for seasonal allergies | Carbzah is a branded generic version of carbinoxamine solution. The price of this product is about 6X greater than the existing generics | NF: all lines of business |
| Dificid (**fidaxomicin**) 200 mg tablets for Clostridioides difficile-associated diarrhea | Generic fidaxomicin recently launched. For Commercial/Exchange, Dificid is currently rebated with similar net cost to the generic. The brand rebate continues with the generic added at the same tier with the same utilization management. | F: IFP, MANF: Medicare, PPO |
| **Sertraline** 150 & 200 mg capsules for major depressive disorder & obsessive-compulsive disorder | Both brand and generic products are $5 or more per capsule, which is significantly more expensive than the tablet formulations which have been generic for a long time and have a MAC price < $0.25 per tablet. | NF: all lines of business |
| **Fluticasone** 50, 100, & 200 mcg/actuation AG inhalers for asthma (Arnuity Ellipta AG) | As a multisource brand product with only a 5% reduction in AWP price, it is significantly more expensive than the true brand product, which has a significant rebate available. For that reason, the AG remains not covered, while the branded product remains preferred on formulary | NF: all lines of business |
| Entresto (**sacubitril-valsartan**) 24-26, 49-51, & 97-103 mg tablets for heart failure | After some legal battles, the temporary injunction preventing generic launch was lifted in late July. Several manufacturers have since launched their generic versions.  | F: all lines of business |

|  |
| --- |
| New or Expanded Formulations  |

|  |  |  |
| --- | --- | --- |
| **Drug** | **Rationale/Alternative** | **Recommendation** |
| **Miudella** (copper IUD) for contraception | This product contains a lower copper content compared to Paragard, which is of unknown clinical significance. It also uses a more flexible material and improved applicator which may decrease pain during insertion and throughout the duration of use.  | NF: Medicare, PPOF: IFP, MA |
| **Livmarli** (maralixibat) 10, 15, 20 & 30 mg tablets for Alagille syndrome & cholestatic pruritus in progressive familial intrahepatic cholestasis | Livmarli initially launched with only an oral solution available. New tablet formulations containing 10, 15, 20, or 30 mg of maralixibat have launched.  | NF: all lines of business |
| **Edurant Ped** (rilpivirine) 2.5 mg tablets for oral suspension for HIV-1 infection | Lower strength rilpivirine tablets for oral suspension launched supporting dosing in pediatrics at the same daily WAC cost as the standard 25 mg tablets used in older patients.  | F: all lines of business |
| **Bucapsol** (buspirone) 7.5, 10, & 15 mg capsules for anxiety | Buspirone oral capsules recently launched at a significantly higher cost than the same strength generically available tablets, which are covered on formulary and can be used instead of the capsules. | NF: all lines of business |
| **Khindivi** (hydrocortisone) 1mg/mL oral solution for Adrenocortical insufficiency &Alkindi (hydrocortisone) sprinkle capsules formulary maintenance | Khindivi is a new oral solution formulation of hydrocortisone used as replacement therapy in pediatric patients = 5 years of age with adrenocortical insufficiency.  | NF: all lines of business |
| **Nilotinib d-tartrate** 50, 150, & 200 mg capsules for Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) | Nilotinib d-tartrate capsules recently launched. They are a different salt form than the generically available nilotinib (Tasigna), however, there is no difference in dosage or administration. Nilotinib d-tartrate capsules are higher cost than the existing generic formulation ($183.59 vs $176.25 per cap) | NF: all lines of business |
| **Yeztugo** (lenacapavir) 300 tablets & 463.5 mg/1.5 mL SQ vials for HIV Pre-Exposure Prophylaxis | Lenacapavir for HIV pre-exposure prophylaxis (PrEP) recently launched under the new brand name Yeztugo. Yeztugo is available in the same tablet and injection formulations as Sunlenca but is indicated for PrEP vs treatment.  | NF: Medicare, PPOF: IFP, MA |
| **Yutrepia** (treprostinil) 26.5, 53, 79.5 & 106 mcg inhalation capsule for pulmonary arterialhypertension & pulmonary hypertension associated with interstitial lung disease | Yutrepia is a new 505(b)(2) approved inhaled treprostinil product. This is marketed to compete with Tyvaso and Tyvaso DPI for the treatment of pulmonary arterial hypertension | NF: all lines of business |
| **Vyvgart Hytrulo** (efgartigimodalfa and hyaluronidase) 1000 mg- 10,000 units/5 mL PFS for generalized myasthenia gravis & chronic inflammatory demyelinating polyneuropathy | A new prefilled syringe formulation has launched which is labeled to allow for self- or caregiver-administration, rather than being limited to healthcare provider administration. | NF: all lines of business |
| **Arbli** (losartan) 10 mg/mL oral suspension for hypertension | A new commercialized losartan oral suspension product has launched under the brand name Arbli. It is indicated for use in children as young as six years old. | NF: all lines of business |
| **Fanapt** (iloperidone) 1, 2, 6, & 8mg + 1, 2, & 6 mg titration packs for schizophrenia & bipolar I | Two new titration packs are launching, to accommodate additional dosing schedules for new starts. | F: Medicare, PPONF: IFPMA: NP |
| Lopressor (**metoprolol**) 10mg/mL oral solution for hypertension & angina | Metoprolol tartrate oral solution is now available in a 10 mg/mL strength  | NF: all lines of business |
| **Averi** (desogestrel-ethinyl estradiol-Fe) 0.15-0.3 mg tablet for contraception | Averi oral contraceptive tablets contain desogestrel, ethinyl estradiol, and iron. The cost is similar to other single-source brand oral contraceptives. | NF: all lines of business |
| **Ibuprofen** 300 mg tablet for pain | A new tablet formulation of ibuprofen was approved through the generic approval pathway. This product provides a 300 mg strength, which has been discontinued for years. $13 per tablet | NF: all lines of business |
| **Dicyclomine** 40 mg tablets for irritable bowel syndrome | A new branded 40 mg strength for dicyclomine tablets has launched at a significantly higher price compared to the generically available 10 mg capsules and 20 mg tablets. | NF: all lines of business |
| **Spevigo** (spesolimab) 300 mg/2 mL PFS for generalized pustular psoriasis | A higher strength prefilled syringe for Spevigo launched allowing for simpler administration, as the full monthly dose can now be administered as just one injection.  | NF: Medicare, PPO, IFPMA: NP |

|  |
| --- |
| Additional Items Reviewed  |

|  |  |
| --- | --- |
| **Item** | **Drugs with New Policies** |
| New Medical Drug Policies (effective 11/15/2025) | * Andembry
* Lynozyfic
* Onapgo
* Yeztugo
* Zevaskyn
* Zusduri
 |